Related Experiment Videos
E4, a new monoclonal antibody identifying a human prostatic cell surface antigen
1Department of Oncology, Uppsala University, Akademiska Sjukhuset, Sweden. Sten.Nilsson@onkologi.uu.se
Cancer Biotherapy & Radiopharmaceuticals
|June 14, 2000
Summary
The E4 monoclonal antibody targets a prostate antigen found in normal and cancerous prostate cells. This antibody shows promise as a diagnostic marker and for targeted prostate cancer therapies.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Prostate cancer diagnosis and treatment require specific biomarkers.
- Monoclonal antibodies offer high specificity for targeted therapies.
Purpose of the Study:
- To characterize the monoclonal antibody E4 for its potential use in prostate cancer diagnostics and therapeutics.
- To identify the expression pattern and molecular characteristics of the E4 antigen.
Main Methods:
- Immunization of mice with human benign prostatic hyperplasia cells to generate monoclonal antibody E4.
- Immunohistochemical analysis of prostate tissues and cell lines (DU 145).
- SDS-PAGE to determine the molecular weight of the target antigen.
Main Results:
- E4 antibody recognizes an antigen highly expressed in normal prostate epithelial cells, benign prostatic hyperplasia, and well- to moderately differentiated prostate adenocarcinomas.
- Poorly differentiated prostate adenocarcinomas showed reduced E4 antigen expression.
- E4 immunoreactivity was localized to the cell surface of the DU 145 cell line.
- SDS-PAGE revealed an antigen molecular weight of approximately 70,000 under reducing conditions.
Conclusions:
- The E4 antibody is a specific marker for prostate tissue, particularly for well- and moderately differentiated adenocarcinomas.
- Its cell surface localization and specific reactivity suggest potential for immunoscintigraphy and targeted radiotherapy in prostate cancer.